TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
1. TGTX to present BRIUMVI data at the ECTRIMS annual meeting. 2. Presentations scheduled for September 24-26, in Barcelona, Spain. 3. BRIUMVI is approved for relapsing multiple sclerosis in the US and Europe. 4. Clinical trials showed favorable results for BRIUMVI against teriflunomide. 5. Upcoming presentations include safety data and real-world clinical experience.